AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24935203 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Number of subjects: 111
Study 24935203 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 111
Study 22576673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (atorvastatin 80 mg)
Number of subjects: 18889
Study 22576673 — intervention group
Group type: COMPARATOR
Intervention: Conventional/low-dose lipid-lowering therapy (atorvastatin 10 mg or simvastatin 20-40 mg)
Number of subjects: 18889
Study 20519962 — intervention group
Group type: EXPERIMENTAL
Intervention: hu12F6mu (2.5, 5, or 10 mg)
Number of subjects: 27
Study 17613574 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial neuromuscular re-education (three sessions per day for six days per week for two weeks)
Number of subjects: 59
Study 17613574 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic measures
Number of subjects: 59
Study 16222308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients with lower socio-economic status
Number of subjects: 609
Study 16222308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 609
Study 16222308 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation
Number of subjects: 609
Study 12151920 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 8
Study 12151920 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 8
Study 10435374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest thallium-201 myocardial SPECT and exercise Tc-99m tetrofosmin first pass and SPECT
Number of subjects: 47
Study 7482625 — intervention group
Group type: EXPERIMENTAL
Intervention: stanazolol
Number of subjects: 9
Study 7482625 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 2301782 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone, 200 micrograms four times daily (T)
Number of subjects: 37
Study 2301782 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler (P)
Number of subjects: 37
Study 2301782 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone (T) in higher compliers
Number of subjects: 37
Study 2301782 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone (T) in lower compliers
Number of subjects: 37
Study 6135874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 43
Study 6135874 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and azathioprine
Number of subjects: 43
Study 29846713 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 7658
Study 29846713 — intervention group
Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 7658
Study 29115354 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily blueberry juice intake (1× dosing)
Number of subjects: 17
Study 29115354 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily blueberry juice intake (⅓ doses taken thrice daily)
Number of subjects: 17
Study 29115354 — intervention group
Group type: COMPARATOR
Intervention: Washout period (7 days)
Number of subjects: 17
Study 27592180 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with RehaCom cognitive training
Number of subjects: 204
Study 27592180 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 204
Study 27592180 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaCom cognitive training
Number of subjects: 204
Study 27592180 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 204
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Myristic acid (14:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (16:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid (18:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentadecanoic acid (15:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptadecanoic acid (17:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidic acid (20:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Behenic acid (22:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricosanoic acid (23:0)
Number of subjects: 12403
Study 25107467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignoceric acid (24:0)
Number of subjects: 12403
Study 22284248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (esomeprazole 40 mg BID, amoxicillin 1g BID for 1 week, followed by esomeprazole 40 mg BID, levofloxacin 500 mg QD, metronidazole 500 mg TID for 1 week)
Number of subjects: 150
Study 22284248 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (esomeprazole 40 mg BID, amoxicillin 1g BID, clarithromycin 500 mg BID for 2 weeks)
Number of subjects: 150
Study 19148112 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy alone
Number of subjects: 60
Study 19148112 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy with kinesthetic stimulation (M/KS)
Number of subjects: 60
Study 19148112 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study 20426913 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-nanocolloid scintigraphy
Number of subjects: 40
Study 20426913 — intervention group
Group type: COMPARATOR
Intervention: Clinical remission criteria
Number of subjects: 40
Study 16271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 45852
Study 16271642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45852
Study 12095065 — intervention group
Group type: EXPERIMENTAL
Intervention: tazarotene plus clindamycin phosphate lotion
Number of subjects: 440
Study 12095065 — intervention group
Group type: EXPERIMENTAL
Intervention: tazarotene plus erythromycin/benzoyl peroxide
Number of subjects: 440
Study 12095065 — intervention group
Group type: EXPERIMENTAL
Intervention: tazarotene plus clindamycin
Number of subjects: 440
Study 12095065 — intervention group
Group type: EXPERIMENTAL
Intervention: tazarotene plus benzoyl peroxide
Number of subjects: 440
Study 9590494 — intervention group
Group type: EXPERIMENTAL
Intervention: IMED Gemini PC‐2TX infusion pump
Number of subjects: 4
Study 9590494 — intervention group
Group type: COMPARATOR
Intervention: Intravenous push method
Number of subjects: 4
Study 8165649 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UF heparin), 10,000 IU s.c. b.d.
Number of subjects: 80
Study 8165649 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (Fragmin), 5000 IU anti‐Factor Xa s.c. b.d.
Number of subjects: 80
Study 17171954 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (F1O2 = 1.0)
Number of subjects: 19
Study 17171954 — intervention group
Group type: COMPARATOR
Intervention: 50% O2 (air‐O2 mixture, F1O2 = 0.5)
Number of subjects: 19
Study 30591095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella group (AG) - Oscillating positive expiratory pressure training
Number of subjects: 69
Study 27116107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices focusing on high value elements (HVEs) for quality improvement goals
Number of subjects: 1597
Study 27116107 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 1597
Study 24715102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Task-MOVING (DTM) group performed a dual-task during the MOVING phase
Number of subjects: 36
Study 24715102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Task-AFTEREFFECT (DTAE) group performed a dual-task during the AFTER phase
Number of subjects: 36
Study 24715102 — intervention group
Group type: COMPARATOR
Intervention: Control group performed no dual task
Number of subjects: 36
Study 22175429 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal teat sealant containing bismuth subnitrate
Number of subjects: 35
Study 22175429 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 35
Study 22175429 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal teat sealant
Number of subjects: 35
Study 21046773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent infiltration solution at 25 degrees C (Group A)
Number of subjects: 15
Study 21046773 — intervention group
Group type: COMPARATOR
Intervention: Tumescent infiltration solution at 37 degrees C (Group B)
Number of subjects: 15
Study 21046773 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 15
Study 18718770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic GSV stripping
Number of subjects: 60
Study 18718770 — intervention group
Group type: COMPARATOR
Intervention: Conventional GSV stripping
Number of subjects: 60
Study 15891319 — intervention group
Group type: EXPERIMENTAL
Intervention: DrotAA (24 microg.kg.hr for 96 hrs)
Number of subjects: 1690
Study 15891319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 12633119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine (N = 13)
Number of subjects: 26
Study 12633119 — intervention group
Group type: COMPARATOR
Intervention: Depot antipsychotic control (N = 13)
Number of subjects: 26
Study 10595865 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study 10595865 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic oral oseltamivir
Number of subjects: 0
Study 9095688 — intervention group
Group type: EXPERIMENTAL
Intervention: One airflow filter on the expiratory limb
Number of subjects: 35
Study 9095688 — intervention group
Group type: COMPARATOR
Intervention: Two airflow filters (one on the inspiratory limb and one on the expiratory limb)
Number of subjects: 35
Study 1989427 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g fish oil/d (omega-3 fatty acid)
Number of subjects: 46
Study 1989427 — intervention group
Group type: COMPARATOR
Intervention: 9 g corn oil/d (omega-6 fatty acid)
Number of subjects: 46
Study 1989427 — intervention group
Group type: EXPERIMENTAL
Intervention: fish oil
Number of subjects: 46
Study 6349914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1 g administered 30 minutes before operation and 3 and 10 hours after)
Number of subjects: 100
Study 6349914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline administered at the same times as cefuroxime)
Number of subjects: 100
Study 31444115 — intervention group
Group type: EXPERIMENTAL
Intervention: Candle Burning (CB)
Number of subjects: 55
Study 31444115 — intervention group
Group type: EXPERIMENTAL
Intervention: Toasting Bread (TB)
Number of subjects: 55
Study 31444115 — intervention group
Group type: EXPERIMENTAL
Intervention: Frying Sausages (FS)
Number of subjects: 55
Study 31444115 — intervention group
Group type: COMPARATOR
Intervention: Control (Sham)
Number of subjects: 55
Study 29702071 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS) in addition to routine physiotherapy (PHY/IS)
Number of subjects: 387
Study 29117475 — intervention group
Group type: EXPERIMENTAL
Intervention: D-blade video
Number of subjects: 52
Study 29117475 — intervention group
Group type: COMPARATOR
Intervention: Direct Macintosh laryngoscope
Number of subjects: 52
Study 24468783 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) combined with pegylated interferon alpha-2b (PEG-IFN) and ribavirin (RBV)
Number of subjects: 8
Study 22747768 — intervention group
Group type: EXPERIMENTAL
Intervention: epoprostenol 1 ng/kg/min
Number of subjects: 90
Study 22747768 — intervention group
Group type: EXPERIMENTAL
Intervention: epoprostenol 2 ng/kg/min
Number of subjects: 90
Study 22747768 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 20083483 — intervention group
Group type: EXPERIMENTAL
Intervention: Steerable sheath (group S)
Number of subjects: 40
Study 20083483 — intervention group
Group type: COMPARATOR
Intervention: Non-steerable sheath (group NS)
Number of subjects: 40
Study 17045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated, 96-well format solid-phase extraction (SPE) method for alendronate determination
Number of subjects: 96
Study 17045443 — intervention group
Group type: COMPARATOR
Intervention: Alendronate sodium tablets (70 mg)
Number of subjects: 96
Study 16494040 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A surgery
Number of subjects: 2792
Study 16494040 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B surgery
Number of subjects: 2792
Study 16494040 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C surgery
Number of subjects: 2792
Study 11349937 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (30 grams daily)
Number of subjects: 15
Study 11349937 — intervention group
Group type: COMPARATOR
Intervention: Control (no placebo)
Number of subjects: 15
Study 9589236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly‐‐>Arg substitution in codon 972 of the insulin receptor substrate‐1 gene in subjects with IGT
Number of subjects: 1106
Study 9589236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly‐‐>Arg substitution in codon 972 of the insulin receptor substrate‐1 gene in subjects with NIDDM
Number of subjects: 1106
Study 9589236 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects aged > 50 years
Number of subjects: 1106
Study 9589236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with IGT or NIDDM
Number of subjects: 1106
Study 9589236 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with the variant allele
Number of subjects: 1106
Study 7744393 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 1,000,000 u intramuscularly daily for 10 days
Number of subjects: 57
Study 7744393 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C and inosine therapy intravenously daily for 10 days
Number of subjects: 57
Study 2601863 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride 50 mg
Number of subjects: 0
Study 2601863 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride 100 mg
Number of subjects: 0
Study 2601863 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 5 mg
Number of subjects: 0
Study 2601863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 4595974 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) 15 mg/kg/day I.V. x 5 given monthly
Number of subjects: 52
Study 4595974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) 10 mg/kg/day I.V. on days 1 to 5; imidazole 4 carboxamide, 5 (3,3 dimethyl 1 triazeno) (ICDT) 3 mg/kg/day I.V. on days 1 and 2; vincristine (VCR) 0.025 mg/kg I.V. on day 1; bis (2 chloroethyl) 1 nitrosourea (BCNU) 1.5 mg/kg I.V. on day 1
Number of subjects: 52
Study 30744600 — intervention group
Group type: COMPARATOR
Intervention: Hospital doctors
Number of subjects: 1749
Study 28237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3·0 mg
Number of subjects: 2254
Study 28237263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2254
Study 26281344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal health locus of control (FHLC) Scale - Internality Scale (FHLC‐I)
Number of subjects: 256
Study 26281344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal health locus of control (FHLC) Scale - Chances Scale (FHLC‐C)
Number of subjects: 256
Study 23489216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan/naproxen sodium
Number of subjects: 20
Study 23489216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21233387 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing assignment before the test
Number of subjects: 0
Study 21233387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18835526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl pyruvate (EP) 7,500 mg administered intravenously starting after the induction of general anesthesia followed by 5 more doses of 7,500 mg every 6 hours.
Number of subjects: 102
Study 18835526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 17907389 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Sanyinjiao (SP 6) at 2/100 Hz, 8-10 mA for 30 min, 3 times a week for 1 month (3 courses total)
Number of subjects: 175
Study 17907389 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Sanyinjiao (SP 6)
Number of subjects: 175
Study 17907389 — intervention group
Group type: COMPARATOR
Intervention: Medication group (nilestriol 2 mg, twice/month for 3 months; medrysone 2 mg, t.i.d. for 10 days from the 3rd month)
Number of subjects: 175
Study 15841580 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium frameworks (test group)
Number of subjects: 126
Study 15841580 — intervention group
Group type: COMPARATOR
Intervention: Gold alloy castings (control group)
Number of subjects: 126
Study 11566440 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake (0.8 g/kg per day)
Number of subjects: 9
Study 11566440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9193324 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC and DZR (after 300 mg/m2 doxorubicin)
Number of subjects: 201
Study 9193324 — intervention group
Group type: COMPARATOR
Intervention: FAC and PLA (before amendment)
Number of subjects: 201
Study 8253942 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 220
Study 8253942 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone
Number of subjects: 220
Study 8253942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 220
Study 4020747 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy
Number of subjects: 0
Study 4020747 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive therapy
Number of subjects: 0
Study 4020747 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (treatment as usual)
Number of subjects: 0
Study 4020747 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual vs Group cognitive therapy
Number of subjects: 0
Study 4020747 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 0
Study 30954675 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive social incentives
Number of subjects: 602
Study 30954675 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive social incentives
Number of subjects: 602
Study 30954675 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative social incentives
Number of subjects: 602
Study 30954675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 602
Study 29602631 — intervention group
Group type: EXPERIMENTAL
Intervention: TAKE-IT intervention (text message, e-mail, visual cue reminders, and coaching)
Number of subjects: 169
Study 29602631 — intervention group
Group type: COMPARATOR
Intervention: Control group (coaching without feedback on adherence data)
Number of subjects: 169
Study 27634158 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic treatment
Number of subjects: 60
Study 27634158 — intervention group
Group type: COMPARATOR
Intervention: Advice to remain active (Control)
Number of subjects: 60
Study 23796045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (3 mg/kg/day)
Number of subjects: 20
Study 23796045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21598242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination weekly docetaxel and carboplatin (cDC)
Number of subjects: 0
Study 21598242 — intervention group
Group type: COMPARATOR
Intervention: Sequential docetaxel followed by carboplatin (sDC)
Number of subjects: 0
Study 19470159 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete CapRI-scheme (cisplatin, Interferon alpha-2b, external beam radiation, and three cycles of 5-fluorouracil continuous infusion)
Number of subjects: 135
Study 19470159 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalated CapRI-scheme (omitting cisplatin)
Number of subjects: 135
Study 19470159 — intervention group
Group type: EXPERIMENTAL
Intervention: Further de-escalated CapRI-scheme (omitting both cisplatin and external beam radiation)
Number of subjects: 135
Study 17487762 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 6 months (less by 10% to their anaerobic threshold)
Number of subjects: 185
Study 17487762 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment without training (Control)
Number of subjects: 185
Study 15141270 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee group (n=133)
Number of subjects: 262
Study 15141270 — intervention group
Group type: COMPARATOR
Intervention: No trainee group (n=129)
Number of subjects: 262
Study 15141270 — intervention group
Group type: EXPERIMENTAL
Intervention: Between group differences
Number of subjects: 262
Study 12972969 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 34
Study 12972969 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 34
Study 10228253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam
Number of subjects: 180
Study 10228253 — intervention group
Group type: COMPARATOR
Intervention: Sedation with intravenous saline (placebo group)
Number of subjects: 180
Study 10228253 — intervention group
Group type: COMPARATOR
Intervention: No intravenous cannula (control group)
Number of subjects: 180
Study 8746143 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass polyalkenoate cement
Number of subjects: 228
Study 8746143 — intervention group
Group type: COMPARATOR
Intervention: Bis glycidyl methacrylate resin
Number of subjects: 228
Study 1829368 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (5 mg once daily)
Number of subjects: 12
Study 1829368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6348314 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam, 15 to 40 mg/day
Number of subjects: 180
Study 6348314 — intervention group
Group type: COMPARATOR
Intervention: sedative-benzodiazepines (less than eight months)
Number of subjects: 180